Malaria is a vector-borne infectious disease caused by the protozoan parasite belonging to the Plasmodium genus (1). The transmission occurs among humans through the bite of the female Anopheles mosquito. This disease is among the top ten causes of death in low-income countries (2) and continues to take a heavy toll on communities, especially in Africa regions. The malaria transmission cycle involves four major elements: the host (human), the parasite, the vector and the environment (3). In the absence of effective vaccine or sustainable treatment options, vector control is the cornerstone of malaria management and is based on prevention of human-host contact and reduction in vector population density (1, 4). The traditional vector control strategies rely on long-lasting insecticidal net (LLIN) distribution and indoor residual sprays (IRS) which have contributed to the decreasing malaria cases and mortality (5, 6). However, vector resistance against the existing insecticides is increasing in natural mosquito populations (7–9).
In the last decade, scientific advances in additional tools for vector control include technologies such as cytoplasmic incompatibility with the use of Wolbachia infection (10); repressible dominant lethal systems in Aedes aegypti (11, 12); Y-chromosome shredding gene drive (13); and the genetic sterilisation of Anopheles sp., known as Sterile Insect Techniques (SIT) (14). The latter technique, SIT, is based on the repeated, high-density release of radio-sterilized males, through gamma radiation, into the environment in order to compete with wild males for mating with the native female anopheles mosquitoes hindering the production of offspring (14). Indeed, mated females will not produce viable offspring, resulting in reduced population numbers or even elimination of the target species. However, instead of exposing males to a source of radiation, sterility could be induced by genetic modification of the mosquito genome and may improve the effectiveness of classical SIT-based approaches (14).
In An. gambiae, one of the major malaria vectors, population supression strategies are already under investigation by targeting the sex determination genes such as the doublesex (dsx) transcription factor gene (15, 16). Therefore, the Anopheles gambiae doublesex gene (Agdsx) represent a useful candidate gene for genetic manipulation and improvement of the alternative mosquito control technologies. Interest in this gene comes from the fact that it undergoes alternative splicing and result in female and male-specific transcripts necessary for sex determination in this species (17). The use of transgenic tools in anopheline mosquitoes through targeting the dsx gene could improve the sterility induction and genetic sexing which are major requirements for SIT technologies. However, the molecular mechanisms underlying gender determination are highly variable. Though it was demonstrated that Yob1 gene (Y-linked) is one of the determining factors of the male sex (18), the molecular pathways controlling the signal of somatic sexual commitment (dsx splicing and regulation) in An. gambiae are not well understood. The only well-known model of the dsx splicing comes from the fly Drosophila melanogaster sex determination pathway (19). The dsx gene acts as a transcription factor targeting several genes which have mostly sex- and tissue-specific functions in fly (20, 21). Transformer (TRA) and Transformer 2 (TRA2) are the key regulatory factors of the female-specific alternative splicing of dsx pre-mRNA while the absence of TRA lead to the male-specific splicing (20). Both TRA and TRA2 are downstream targets of the Sex lethal gene (Sxl) product (19). Unfortunately, An. gambiae dsx gene (Agdsx) has a different structure suggesting that Agdsx sex-specific splicing event is caused by a mechanism different from that of the D. melanogaster dsx (17, 22).
In mammalian cells, the presence of genetic variations such as single nucleotide polymorphisms (SNPs) within the donor and acceptor splice sites could influence splicing and might lead to changes in normal splicing pattern (23–25). Donor sites (5’-splice site) are defined by GT dinucleotide at the 5’ end of exon-intron border, while AG dinucleotide defined acceptor sites (3’-splice site) at the 3’ end of intron-exon border (26). Thus, we hypothesize that SNPs could occur in the Agdsx acceptor and donor splice sites that might result in the splice variation With this in mind, the current report seeks to screen Agdsx for single-nucleotide polymorphisms (SNPs) that could be associated with alternative splicing.